CR11284A - Sulfonamidas como moduladores de trpm8 - Google Patents

Sulfonamidas como moduladores de trpm8

Info

Publication number
CR11284A
CR11284A CR11284A CR11284A CR11284A CR 11284 A CR11284 A CR 11284A CR 11284 A CR11284 A CR 11284A CR 11284 A CR11284 A CR 11284A CR 11284 A CR11284 A CR 11284A
Authority
CR
Costa Rica
Prior art keywords
sulfonamids
trpm8 modulators
trpm8
modulators
syndromes
Prior art date
Application number
CR11284A
Other languages
English (en)
Inventor
T Branum Shawn
W Colburn Raymond
L Dax Scott
M Flores Christopher
C Jetter Michele
Lu Yi
Ludovici Donald
J Macielag Mark
M Matthews Jay
J Mcnally James
M Reany Laura
K Russell Ronald
Qin Ning
Teleha Christopher
M Wells Kenneth
C Youells Scott
A Youngman Mark
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39772848&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11284(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR11284A publication Critical patent/CR11284A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen compuestos, composiciones y metodos para tratar varias enfermedades, sindromes, afecciones, trastornos, incluso el dolor.
CR11284A 2007-07-18 2010-02-18 Sulfonamidas como moduladores de trpm8 CR11284A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95045607P 2007-07-18 2007-07-18

Publications (1)

Publication Number Publication Date
CR11284A true CR11284A (es) 2010-08-18

Family

ID=39772848

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11284A CR11284A (es) 2007-07-18 2010-02-18 Sulfonamidas como moduladores de trpm8

Country Status (27)

Country Link
US (3) US8153682B2 (es)
EP (1) EP2183239B1 (es)
JP (1) JP5539868B2 (es)
KR (1) KR101538391B1 (es)
CN (1) CN101801949B (es)
AR (1) AR067602A1 (es)
AU (3) AU2008275927B8 (es)
BR (1) BRPI0815096A2 (es)
CA (1) CA2693159C (es)
CL (1) CL2008002132A1 (es)
CO (1) CO6251375A2 (es)
CR (1) CR11284A (es)
EA (1) EA201070158A1 (es)
EC (1) ECSP109921A (es)
GT (1) GT201000015A (es)
IL (1) IL203295A (es)
JO (1) JO2853B1 (es)
MX (1) MX2010000690A (es)
MY (1) MY153971A (es)
NI (1) NI201000013A (es)
NZ (1) NZ582555A (es)
PA (1) PA8790401A1 (es)
TW (1) TWI446909B (es)
UA (1) UA99624C2 (es)
UY (1) UY31239A1 (es)
WO (1) WO2009012430A1 (es)
ZA (1) ZA201001157B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8216547B2 (en) * 2008-07-18 2012-07-10 Janssen Pharmaceutica Nv Radiolabelled TRP M8 receptor ligands
MX339867B (es) * 2008-10-27 2016-06-14 Alza Corp * Forma de dosificacion oral de liberacion prolongada de acetaminofeno/tramadol.
WO2010080397A1 (en) * 2008-12-18 2010-07-15 Janssen Pharmaceutica Nv Sulfamides as trpm8 modulators
EP2379496B1 (en) * 2008-12-18 2013-12-04 Janssen Pharmaceutica, N.V. Sulfonamides as trpm8 modulators
EP2417123A2 (en) 2009-04-06 2012-02-15 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
EP2424517A4 (en) * 2009-05-01 2013-01-23 Raqualia Pharma Inc SULFAMOYLBENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS
TW201105681A (en) * 2009-06-10 2011-02-16 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as TRPM8 channel modulators
TW201103941A (en) * 2009-06-10 2011-02-01 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as TRPM8 channel modulators
ES2352398B1 (es) * 2009-06-25 2011-09-29 Institut Univ. De Ciencia I Tecnologia S.A. N-fenetilsulfonamidas-n-sustituidas para la identificacion de actividad biologica y farmacologica.
US20120122920A1 (en) * 2009-06-26 2012-05-17 Josep Castells Boliart Libraries of n-substituted-n-phenylethylsulfonamides for drug discovery
EP2448581B1 (en) 2009-06-29 2016-12-07 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
CR20170071A (es) 2009-06-29 2017-03-28 Agios Pharmaceuticals Inc Compuestos terapeuticos y composiciones
US20120122710A1 (en) * 2009-07-01 2012-05-17 Josep Castells Boliart Libraries of n-substituted-n-phenylethylsulfonamides for the identification of biological and pharmacological activity
EP2493863B1 (en) * 2009-10-30 2015-02-25 Janssen Pharmaceutica NV Phenoxy-substituted pyrimidines as opioid receptor modulators
DE102010002558A1 (de) 2009-11-20 2011-06-01 Symrise Ag Verwendung physiologischer Kühlwirkstoffe und Mittel enthaltend solche Wirkstoffe
US8829026B2 (en) 2010-10-01 2014-09-09 Raqualia Pharma Inc. Sulfamoyl benzoic acid heterobicyclic derivatives as TRPM8 antagonists
US8618150B2 (en) 2010-12-09 2013-12-31 Janssen Pharmaceutica, Nv Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators
EP2651898B1 (en) 2010-12-17 2015-12-09 Agios Pharmaceuticals, Inc. Novel n-(4-(azetidine-1-carbonyl)phenyl)-(hetero-)arylsulfonamide derivatives as pyruvate kinase m2 (pmk2) modulators
WO2012088314A1 (en) * 2010-12-21 2012-06-28 Agios Pharmaceuticals, Inc. Bicyclic pkm2 activators
US8906384B2 (en) * 2010-12-22 2014-12-09 The United States Of America As Represented By The Secretary Of Agriculture Antiviral activity of bovine type III interferon against foot-and-mouth disease virus
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
EP2481727A1 (en) 2011-01-28 2012-08-01 Dompe S.p.A. TRPM8 receptor antagonists
WO2012120398A1 (en) 2011-03-04 2012-09-13 Pfizer Limited Aryl substituted carboxamide derivatives as trpm8 modulators
CA2826678C (en) * 2011-03-16 2016-07-26 Mitsubishi Tanabe Pharma Corporation Sulfonamide compounds having trpm8 antagonistic activity
ME03074B (me) 2011-05-03 2019-01-20 Agios Pharmaceuticals Inc Akтivatori piruvat kinaze za upotrebu u terapiji
WO2012151440A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
RS57389B1 (sr) 2011-12-19 2018-09-28 Dompe Farm Spa Antagonisti trpm8
EP2606888A1 (en) 2011-12-19 2013-06-26 Dompe' S.P.A. Trpm8 antagonists
JP5985453B2 (ja) * 2012-09-14 2016-09-06 田辺三菱製薬株式会社 医薬組成物
JP6127056B2 (ja) * 2012-09-14 2017-05-10 田辺三菱製薬株式会社 スルホンアミド化合物
EP2774919A1 (en) * 2013-03-06 2014-09-10 Pharmeste S.R.L. In Liquidazione Novel sulfonamide TRPA1 receptor antagonists
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
CN105263481A (zh) * 2013-05-24 2016-01-20 雀巢产品技术援助有限公司 使用薄荷醇和/或冰素治疗或预防抑郁
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
KR102251681B1 (ko) * 2013-08-23 2021-05-14 바스프 에스이 말단 헤테로아릴시아노비닐렌 기를 갖는 화합물 및 이의 유기 태양 전지에서의 용도
RS58590B1 (sr) 2014-06-23 2019-05-31 Dompe Farm Spa Derivati 2-aril-4-hidroksi-1,3-tiazola korisni kao inhibitori trpm8 u lečenju neuralgije, bola, copd i astme
MA44392B1 (fr) 2015-06-11 2023-10-31 Agios Pharmaceuticals Inc Procédés d'utilisation d'activateurs de la pyruvate kinase
JP6454418B2 (ja) 2015-06-23 2019-01-16 キッセイ薬品工業株式会社 ピラゾール誘導体、またはその薬理学的に許容される塩
WO2017062570A1 (en) 2015-10-06 2017-04-13 Ora, Inc. Transient receptor potential cation channel subfamily m member 8 (trpm8) antagonists and methods of use
EP3184524A1 (en) * 2015-12-21 2017-06-28 Dompé farmaceutici S.p.A. 4-hydroxy-2-phenyl-1,3-thiazol-5-yl methanone derivatives as trpm8 antagonists
EP3535269B1 (en) * 2016-11-02 2020-12-09 Janssen Pharmaceutica NV [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors
JP7231617B2 (ja) 2017-08-31 2023-03-01 ビーエーエスエフ ソシエタス・ヨーロピア 生理学的冷涼活性成分の使用、及びそのような活性成分を含む組成物
JP7531508B2 (ja) 2019-04-30 2024-08-09 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド ベンゾチオフェン化合物、その調製方法およびその使用
AU2021305165A1 (en) 2020-07-06 2023-02-02 Tactogen Inc Advantageous benzothiophene compositions for mental disorders or enhancement
RU2756587C9 (ru) * 2021-02-12 2021-10-12 Акционерное общество "Отисифарм" Производные 2-ацетамидо-6-гидрокси-бензотиофена и их фармацевтически приемлемые соли, обладающие противовирусной активностью
GB202117129D0 (en) * 2021-11-26 2022-01-12 Epidarex Exeed Ltd Compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725141D0 (en) * 1997-11-27 1998-01-28 Pharmacia & Upjohn Spa Benzenesulfonamide compounds
DE10215321A1 (de) 2002-04-02 2003-10-23 Metagen Pharmaceuticals Gmbh Trp-p8 Splice Varianten und regulatorische RNA
WO2006040103A1 (en) 2004-10-13 2006-04-20 Bayer Healthcare Ag Use of cold menthol receptor modulators for the treatment of respiratory disorders
WO2006040136A1 (en) * 2004-10-13 2006-04-20 Bayer Healthcare Ag Substituted 4-benzyloxy-phenylmethylamide derivatives as cold menthol receptor-1 (cmr-1) antagonists for the treatment of urological disorder
US20100160255A1 (en) 2005-07-29 2010-06-24 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
WO2007017093A1 (en) 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted 2-benzyloxy-benzoic acid amide derivatives
WO2007017092A1 (en) * 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted 4-benzyloxy-benzoic acid amide derivatives
WO2007017094A1 (en) * 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted benzyloxy-phenylmethylcarbamate derivatives
JP5404388B2 (ja) * 2006-05-10 2014-01-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 冷メントール受容体−１拮抗薬

Also Published As

Publication number Publication date
EP2183239B1 (en) 2012-08-22
AU2016204436A1 (en) 2016-07-21
UA99624C2 (uk) 2012-09-10
JP2010533734A (ja) 2010-10-28
ZA201001157B (en) 2011-04-28
CN101801949B (zh) 2014-09-24
EA201070158A1 (ru) 2010-08-30
US8153682B2 (en) 2012-04-10
CA2693159C (en) 2016-05-24
US20120190674A1 (en) 2012-07-26
KR101538391B1 (ko) 2015-07-21
NI201000013A (es) 2010-07-22
ECSP109921A (es) 2010-02-26
CN101801949A (zh) 2010-08-11
EP2183239A1 (en) 2010-05-12
TWI446909B (zh) 2014-08-01
UY31239A1 (es) 2009-03-31
US20090264474A1 (en) 2009-10-22
US20140315899A1 (en) 2014-10-23
AU2008275927A1 (en) 2009-01-22
AU2008275927B2 (en) 2014-08-07
KR20100049598A (ko) 2010-05-12
JP5539868B2 (ja) 2014-07-02
AU2014203797A1 (en) 2014-07-31
TW200918045A (en) 2009-05-01
CL2008002132A1 (es) 2009-03-06
AR067602A1 (es) 2009-10-14
IL203295A (en) 2015-09-24
JO2853B1 (en) 2015-03-15
GT201000015A (es) 2012-03-12
CA2693159A1 (en) 2009-01-22
US8809327B2 (en) 2014-08-19
CO6251375A2 (es) 2011-02-21
MX2010000690A (es) 2010-06-25
US9434711B2 (en) 2016-09-06
BRPI0815096A2 (pt) 2015-07-14
WO2009012430A1 (en) 2009-01-22
PA8790401A1 (es) 2009-03-31
MY153971A (en) 2015-04-30
AU2008275927B8 (en) 2014-08-14
NZ582555A (en) 2012-06-29

Similar Documents

Publication Publication Date Title
CR11284A (es) Sulfonamidas como moduladores de trpm8
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
CR20110477A (es) Inhibidores de enzimas de proteina cinasa activadas por mitogeno p38
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
BRPI0818672A2 (pt) 2'-fluor-2'-desoxitetra-hidrouridinas como inibidores da citidina desaminase
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BRPI0917017B8 (pt) inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
ECSP11010798A (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
SV2010003593A (es) Nuevos herbicidas
UY30987A1 (es) 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
ECSP099502A (es) 4-fenil-piran-3,5-dionas, 4-fenil-tiopiran-3,5-dionas y ciclohexantrionas como nuevos herbicidas
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
MA32811B1 (fr) Nouveaux composés
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
BRPI0908334A2 (pt) kit, composição, produto ou medicamento para tratar comprometimento cognitivo
ECSP099675A (es) Compuestos heterocíclicos, composición y métodos de uso
ECSP109923A (es) Bromhidrato de bupropion y aplicaciones terapéuticas
PA8676401A1 (es) Metodos para purificar tigeciclina
CO6721048A2 (es) Anticuerpos que se unen a notum pectinacetilesterasa
ECSP11010867A (es) Compuestos novedosos de fenilamino-isonicotinamida
UY31760A (es) Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de leucotrieno a4 hidrolasa
DOP2006000061A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)